Contracts › 75N93024C00087
75N93024C00087: Further Characterization and Validation of Monoclonal Antibodies to Study Respiratory
Awarded to Ampersand Biosciences Llc by National Institutes of Health (NIH).
$1.1Mobligated
$1.1Mpotential value
28 March 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93024C00087 |
|---|---|
| Awardee | Ampersand Biosciences Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NY |
| Offers received | 12 |
| Period of performance | 30 September 2024 to 28 March 2027 |
| Potential end | 29 March 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 06 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record